Efficacy of Neostigmine as an Adjuvant to Bupivacaine in Ultrasound-guided Transversus Abdominis Plane Block as a Postoperative Analgesia After Caesarean Delivery.

Cesarean birth is a common surgical procedure. After cesarean birth, postsurgical pain may delay recovery, interfere with maternal-newborn bonding, and reduce the breastfeeding if not adequately controlled. Postpartum analgesia has become a common concern.
Many adjuvant drugs used for peripheral nerve blocks as( N-methyl-d-aspartate (NMDA) receptor antagonists , Magnesium , Ephedrine , Dexamesathone , Fentanyl , Midazolam and Neostigmine) The potential of neostigmine as an adjuvant in peripheral nerve block is through its action to increase acetylcholine at muscarinic junctions of peripheral nerves. 500 mcg neostigmine was used as adjuvant to local anesthetic in an axillary brachial plexus block leads to decreased pain and less use of analgesics in the first 24 hours postoperatively with no incidence of adverse effects.

Start Date01 Dec 2025

Sponsor / Collaborator

Mansoura University

NCT06736392 / Not yet recruitingPhase 2IIT

Efficacy of Dexmedetomidine As an Adjuvant to Bupivacaine in Ultrasound Guided Pericapsular Nerve Group Block for Postoperative Analgesia During Spinal Anesthesia in Hip Replacement Surgeries, a Randomized Controlled Study

Our aim will be to investigate the efficacy of dexmedetomidine as an adjuvant to bupivacaine in ultrasound guided pericapsular nerve group (PENG) block for postoperative analgesia in hip replacement surgeries.
* Our primary outcome of the study: total amount of postoperative morphine consumption in the first 24h postoperative.
* Our secondary outcome of the study: postoperative analgesia assessed by pain score (by Visual Analog Scale)

Start Date01 Mar 2025

Sponsor / Collaborator

Assiut University

NCT06737341 / Not yet recruitingPhase 4IIT

Effect of Bupivacaine Liposomes or Bupivacaine for Ultrasound-guided CMB on Postoperative Analgesia in Laparoscopic Hepatobiliary Pancreatic Surgery: a Prospective, Single Blind, Completely Randomized, Active Controlled Clinical Trial

Numerous studies have confirmed that regional analgesia using peripheral nerve block has great potential for perioperative analgesia in abdominal surgery. Ultrasound guided costal margin block (CMB) is a new regional anesthesia technique that has been proven to compensate for the analgesic effects of regional analgesia techniques such as transverse abdominal muscle plane (TAP) and rectus abdominis sheath (RSB) on mid abdominal incisions, but it is difficult to meet the analgesic needs of anterior and outer abdominal wall incisions. According to relevant anatomy and research, the application of local anesthetics along the rib margin under the rectus abdominis muscle or under the external oblique muscle on the rib surface can block the lateral and anterior cutaneous branches of the thoracoabdominal nerve, known as CMB. Ultrasound guided CMB requires the injection of local anesthetics onto the surface of the rib along the plane below the rectus abdominis and oblique muscles, covering most of the upper abdominal incision pain. However, there are few reports on other types of upper abdominal surgeries such as liver, gallbladder, and pancreas surgeries.
Bupivacaine liposomes are an important innovation, which encapsulate bupivacaine in polycystic liposomes using DepoFoam technology to achieve slow drug release and effectively prolong pain relief time by up to 72 hours. This ultra long acting local anesthetic has significant advantages in reducing opioid use, improving analgesic satisfaction, reducing complications, and shortening hospital stays, and has been applied in the ERAS concept.
The investigators designed a prospective, single blind, randomized, active controlled clinical trial to investigate the effect of bupivacaine liposomes in combination with bupivacaine mixture or bupivacaine alone for ultrasound-guided bilateral CMB on postoperative analgesia in patients undergoing laparoscopic hepatobiliary pancreatic surgery. Our main hypothesis is that the use of bupivacaine liposomes and a mixture of bupivacaine for ultrasound-guided CMB in a multimodal analgesia regimen can more effectively reduce the dosage of intravenous patient-controlled analgesia (PCA) opiates within 72 hours after laparoscopic hepatobiliary pancreatic surgery compared to using bupivacaine alone. Secondary outcomes include the dosage of PCA opiates within 24-48 hours, pain score values, patient satisfaction, adverse reactions, and complications.

Start Date01 Feb 2025

Sponsor / Collaborator

Huazhong University of Science & Technology

100 Clinical Results associated with Bupivacaine

100 Translational Medicine associated with Bupivacaine

100 Patents (Medical) associated with Bupivacaine

14,708

Literatures (Medical) associated with Bupivacaine

01 Feb 2025·JOURNAL OF CLINICAL ANESTHESIA

Intertransverse process block (ITPB) at the retro-superior costotransverse ligament (retro-SCTL) space: Evaluation of local anesthetic spread using MRI and sensory blockade in healthy volunteers

Article

Author: Pakpirom, Jatuporn ; Karmakar, Manoj Kumar ; Siriwanarangsun, Palanan ; Pangthipampai, Pawinee ; Sivakumar, Ranjith Kumar

BACKGROUND:

This study evaluated the spread of a local anesthetic, using MRI and sensory blockade, after an intertransverse process block (ITPB) at the medial aspect of the retro-superior costotransverse ligament (retro-SCTL) space - the medial retro-SCTL space block.

METHODS:

Ten healthy volunteers received a single-injection ultrasound-guided medial retro-SCTL space block at the T4-T5 level using a mixture of 10 ml 0.5 % bupivacaine with 0.5 ml gadolinium. At 15 min, they underwent a high resolution, fat suppressed, T1 weighted MRI scan of the cervicothoracic spine. Loss of sensation to cold was assessed at 15 and 60 min, and then hourly for 5-h, after the block.

RESULTS:

MRI showed consistent (100 %) spread of local anesthetic to the intercostal and paravertebral spaces, anterolateral aspect of the vertebral body (sympathetic chain), costotransverse space, neural foramina, and epidural space in all participants. However, sensory blockade was variable across the ipsilateral hemithorax. Hypoesthesia was more common than anesthesia in both the anterior (median [IQR], 3.5 [2-5] vs 0 [0-1.25], p < 0.001) and posterior (median [IQR], 6[3-7] vs 2[1-3], p < 0.001) hemithorax. Additionally, more dermatomes exhibited anesthesia in the posterior compared to the anterior hemithorax (median [IQR], 2[1-3] vs 0[0-1.25], p = 0.01). A variable number of contralateral dermatomes were also affected in 3 (30 %) volunteers. There was no statistically significant correlation between the local anesthetic spread and the number of hypoesthetic (r = 0.53, p = 0.11) or anesthetic (r = 0.09, p = 0.78) dermatomes on the ipsilateral hemithorax.

CONCLUSIONS:

A single-injection medial retro-SCTL space block, at the T4-T5 level with 10.5 ml of local anesthetic, consistently spreads to the ipsilateral intercostal and paravertebral spaces, sympathetic chain, costotransverse space, neural foramina and epidural space, but produces ipsilateral sensory blockade that is variable and wider over the posterior than anterior hemithorax.

01 Jan 2025·Journal of veterinary dentistry

The Effectiveness of Liposome-Encapsulated Bupivacaine Compared to Standard Bupivacaine for Anesthesia of the Maxilla in Dogs

Article

Author: Bartholomew, Kyle ; Smith, Lesley J.

Medical and surgical procedures involving the canine maxilla can be painful both during and for several hours post-procedure. The length of this pain may exceed the predicted duration of standard bupivacaine or lidocaine. The goal of this study was to determine the duration and efficacy of sensory blockade of the maxilla produced by liposome-encapsulated bupivacaine (LB), compared to standard bupivacaine (B) or saline (0.9% NaCl) (S), when administered as a modified maxillary nerve block in dogs. Eight maxillae were studied bilaterally from 4 healthy dogs of the same breed and similar age. This prospective, randomized, crossover, blinded study evaluated a modified maxillary nerve block using 1.3% LB at 0.1 mL/kg, 0.5% B, or S at an equivalent volume. An electronic von Frey aesthesiometer (VFA) was used to evaluate mechanical nociceptive thresholds at 4 locations on each hemimaxilla at baseline and at specific intervals up to 72-h post-treatment. Both B and LB treatments resulted in significantly higher VFA thresholds when compared to S. Dogs that received B had VFA thresholds significantly higher than S for 5 to 6 h. Dogs that received LB had thresholds significantly higher than S for 6 to 12 h depending on the site of measurement. No complications were observed. Maxillary nerve block with B provided up to 6 h, and LB 12 h, of sensory blockade depending on the site tested.

01 Jan 2025·ANAESTHESIA

Combined spinal‐epidural vs. dural puncture epidural techniques for labour analgesia: a randomised controlled trial*

Article

Author: Habib, Ashraf S. ; Padilla, Andrew ; Fuller, Matthew ; Rubright, Samantha M. ; Pham, Trung ; Craig, Amanda ; Zang, Hannah

Summary:

Background:

The dural puncture epidural technique is a modification of the combined spinal‐epidural technique. Data comparing the two techniques are limited. We performed this randomised study to compare the quality of labour analgesia following initiation of analgesia with the dural puncture epidural vs. the combined spinal‐epidural technique.

Methods:

Term parturients requesting labour epidural analgesia were allocated randomly to receive either dural puncture epidural or combined spinal‐epidural. Analgesia was initiated with 2 mg intrathecal bupivacaine and 10 μg fentanyl in parturients allocated to the combined spinal‐epidural group and with 20 ml ropivacaine 0.1% with 2 μg.ml‐1 fentanyl in parturients allocated to the dural puncture epidural group. Analgesia was maintained using patient‐controlled epidural analgesia with programmed intermittent epidural boluses. The primary outcome of the study was the quality of labour analgesia, which was defined by a composite of five components: asymmetric block after 30 min of initiation (difference in sensory level of more than two dermatomes); epidural top‐up interventions; catheter adjustment; catheter replacement; and failed conversion to neuraxial anaesthesia for caesarean delivery, requiring general anaesthesia or replacement of the neuraxial block.

Results:

One hundred parturients were included in the analysis (48 combined spinal‐epidural, 52 dural puncture epidural). There were no significant differences between the two groups in the primary composite outcome of quality of analgesia (33% in the combined spinal‐epidural group vs. 25% in the dural puncture epidural group), risk ratio (95%CI) 0.75 (0.40–1.39); p = 0.486. Median (IQR [range]) pain scores at 15 min were significantly lower in patients allocated to the combined spinal‐epidural group compared with the dural puncture epidural group (0 (0–1[0–8]) vs. 1 (0–4 [0–10]); p = 0.018).

Conclusions:

There were no significant differences in the quality of labour analgesia following initiation of a combined spinal‐epidural compared with a dural puncture epidural technique.

176

News (Medical) associated with Bupivacaine

20 Dec 2024

·www.globenewswire.com

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical’s recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. “We are encouraged to see that the product will advance to Phase 3 trials in painful lumbosacral radiculopathy, pending discussions with regulators,” said Eric Lang, Channel’s Chief Medical Officer. “While both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that an over expression of NaV1.8 leads to moderate pain whereas an overexpression of NaV1.7 leads to debilitating pain morbidities, and we believe that NaV1.7 inhibition may be a more potent therapy for pain treatment.” Characteristics of Selective NaV1.7 Inhibition NaV1.7 is a well-studied drug target with strong genetic validation — studies of inheritable pain disorders demonstrate that the spectrum of NaV1.7 activity validates the importance of this target. Lack of NaV1.7 activity leads to the inability to sense pain, whereas NaV1.7 gain of function leads to severe pain. Modulation of NaV1.7, therefore, should be an effective mechanism for decreasing pain. “Channel Therapeutics has chosen a three-pronged approach for our NaV1.7 molecule to demonstrate the utility of this target. We are utilizing an oral NaV1.7 inhibitor for the potential treatment of neuropathic pain starting with Idiopathic Small Fiber neuropathy and Erythromelalgia, a novel eye drop formulation of a NaV1.7 inhibitor to treat eye pain and a novel slow-release depot formulation NaV1.7 inhibitor for post-surgical nerve blocks,” stated Frank Knuettel II, Chief Executive Officer of Channel. “The important differences between NaV1.7 and NaV1.8 not only informs but also differentiates Channel Therapeutics’ approaches to clinical development of the Company’s selective sodium channel blockers CC8464, CT2000 and CT3000. We are very encouraged by the recent data that we have seen from our ongoing programs, including the results from our in vivo nerve block results published earlier this week. As such, we look forward to the upcoming studies and data readouts in 2025 which will serve as critical milestones for which to further substantiate the merits of Channel’s clinical development plan,” Mr. Knuettel concluded. About Channel Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit www.channeltherapeutics.com or follow us on social media. Forward-Looking Statements This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the Company’s belief that nerve blocks with its NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain, (ii) the Company’s belief the Company’s NaV1.7 inhibitor has the potential to improve on existing postoperative therapeutic options while opening the door for success with the Company’s other programs, (iii) the Company’s belief that the NaV1.7 inhibitor may offer a better option for post-surgical physical therapy as compared to bupivacaine, (iv) the Company’s belief that investors should feel encouraged that the Company has a strong development path towards successfully launching drugs with considerable market opportunities, and (iv) the timing of expected results on the Company’s eye drops for the treatment of various types of eye pain. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value or that the Company’s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law. Channel Media and Investor Inquiries:Mike MoyerManaging Director, LifeSci Advisors, LLCmmoyer@lifesciadvisors.com

Phase 2

18 Dec 2024

·www.globenewswire.com

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it achieved its endpoints in two pre-clinical in vivo models of the Company’s nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration. “We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain,” stated Dr. Eric Lang, Chief Medical Officer of Channel. “Additionally, we believe this drug has the potential to improve on existing postoperative therapeutic options while opening the door for success with our other programs,” concluded Dr. Lang. About the trial The Company performed a thermal hyperalgesia test in rodents with a placebo arm, bupivacaine arm and four arms of the main formulations of the Company’s molecule. The Company also performed a mechanical allodynia test in rodents with the same arms as above. For both models, the drugs were administered as a sciatic nerve block. All four Company formulations showed a depot effect in excess of four days, an improvement over bupivacaine, the current standard of care. Results The results of the thermal hyperalgesia results are shown in the chart below. After thirty minutes, three of the four formulations showed materially better efficacy than bupivacaine, with each of the three being statistically superior to placebo for more than two days longer than bupivacaine. One of the formulations remained statistically superior to placebo for more than four days. Further, as NaV1.7 does not have an impact on mobility, this approach may offer a better option for post-surgical physical therapy as current nerve block therapies cause temporary paralysis in the affected area. Similarly for the mechanical allodynia test results, three of the four formulations showed statistically better efficacy for a longer duration of time than bupivacaine. The mechanical allodynia test is shorter in duration, reflecting the subject’s innate swift recovery rate to surgical incisions. Nonetheless, the results mirrored the successful results set forth with the thermal hyperalgesia test. “These results support our belief that NaV1.7 is a potent and effective target for the development of drugs for the treatment of pain,” stated Frank Knuettel II, Chief Executive Officer of Channel. “With these results, investors should feel encouraged that we have a strong development path towards successfully launching drugs with considerable market opportunities,” Mr. Knuettel concluded. According to BioSpace, the post-operative global pain market was valued at $2.6 billion in 2023, of which, Exparel, a bupivacaine liposome injectable suspension, generated approximately $538 million in revenue. It is this existing market that the Company is tackling, as well as the post-surgical opioid market opportunity, as these results show potential efficacy for a long period of time, which should reduce post-surgical opioid usage. Results are expected for the studies conducted on the Company’s eye drops for the treatment of various types of eye pain – including severe dry eye, corneal abrasions, surgical intervention and other indications – in late January 2025. About Channel Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit www.channeltherapeutics.com or follow us on social media. Forward-Looking Statements This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the Company’s belief that nerve blocks with its NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain, (ii) the Company’s belief the Company’s NaV1.7 inhibitor has the potential to improve on existing postoperative therapeutic options while opening the door for success with the Company’s other programs, (iii) the Company’s belief that the NaV1.7 inhibitor may offer a better option for post-surgical physical therapy as compared to bupivacaine, (iv) the Company’s belief that investors should feel encouraged that the Company has a strong development path towards successfully launching drugs with considerable market opportunities, and (iv) the timing of expected results on the Company’s eye drops for the treatment of various types of eye pain. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value or that the Company’s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law. Channel Media and Investor Inquires: For Investor Inquiries:Mike MoyerManaging Director, LifeSci Advisors, LLCmmoyer@lifesciadvisors.com

Clinical Result

04 Dec 2024

·www.businesswire.com

Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery

SAN JOSE, Calif.--( BUSINESS WIRE )-- Allay Therapeutics , a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for its lead investigational product ATX101 for treatment of postsurgical pain following TKA procedures in adults. This BTD was granted based on clinical data from a Phase 2 exploratory dose-ranging trial for the treatment of Post-Surgical Pain following Total Knee Arthroplasty (TKA), or replacement. “ We’re delighted that the FDA granted Breakthrough Therapy designation for ATX101, which we believe recognizes the clear unmet need for novel non-opioid therapies that may provide extended pain relief to patients in the weeks following TKA surgeries. Despite decades of development efforts, current treatment methods provide only a few days of pain relief with complicated treatment regimens. ATX101 is designed to provide patients weeks of pain relief enabling an active recovery with less opioids used and less opioid-related side effects and risks,” stated Sharon Hall, SVP of Regulatory Affairs at Allay Therapeutics. “ This BTD will allow us to work closely with the FDA to efficiently advance the ATX101 development program through its clinical and regulatory milestones, and eventual NDA filing. Our planned Phase 2B registrational trial will start early next year with leading investigative pain centers in the U.S. to fully assess ATX101’s potential impact on patient’s pain and recovery following painful total knee replacement surgeries.” The BTD is supported by Allay’s recently completed dose-ranging Phase 2 exploratory trial (n=112) of ATX101 as compared to (SOC) active comparator, bupivacaine. Data showed that ATX101 achieved sustained, clinically meaningful post-surgical pain relief for up to four weeks following TKA compared to the standard of care. Treatment with ATX101 resulted in a decrease in opioid use as well as a decrease in opioid-related side effects and meaningful improvements in functional activities and satisfaction up to 60 days following surgery. FDA’s Breakthrough Therapy program is designed to expedite development review of drugs intended to treat a serious or life-threatening condition for which preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapies. Under the designation, the FDA provides intensive guidance, organizational commitment involving senior managers, and eligibility for rolling review and other actions to expedite review. To learn more about Breakthrough Therapy designation, click here . About ATX101 ATX101 is a novel investigational configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty (TKA, or replacement), a common orthopedic surgery. ATX101 has a high density of drug within its small footprint to allow for ultra-sustained analgesia. It is placed in minutes at the end of standard surgery to deliver its analgesic effect over weeks before eventually dissolving into water and carbon dioxide. The simple procedure does not require specialized training and is intended to replace the existing complex mix of analgesic products used for shorter-term pain management in the post-surgical setting. ATX101 is an investigational product that has not been approved by the U.S. Food and Drug Administration. About Allay Therapeutics Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available. Our platform and vision were shaped by The Foundry incubator and Lightstone Venture’s Singapore Fund. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at allaytx.com .

Phase 2Clinical ResultBreakthrough TherapyFast Track

100 Deals associated with Bupivacaine

External Link

KEGG	Wiki	ATC	Drug Bank
D07552	Bupivacaine	N01BB01	DB00297

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	US	Pacira Biosciences, Inc.	28 Oct 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Back Pain	Phase 3	US	Pacira Biosciences, Inc.	30 Apr 2024
Complication	Phase 3	US	Pacira Biosciences, Inc.	30 Apr 2024
Osteoarthritis, Knee	Phase 3	US	Pacira Biosciences, Inc.	18 Jan 2022
Nausea	Phase 3	US	Pacira Biosciences, Inc.	22 Oct 2021
Pain	Phase 3	US	Pacira Biosciences, Inc.	22 Oct 2021
Analgesia	Phase 3	US	Pacira Biosciences, Inc.	14 Apr 2021
Leg Injuries	Phase 3	US	Pacira Biosciences, Inc.	20 Oct 2020
Ankylosis	Phase 3	-	Pacira Biosciences, Inc.	15 Jun 2020
Metatarsus Varus	Phase 3	-	Pacira Biosciences, Inc.	15 Jun 2020
Shoulder Pain	Phase 3	-	Pacira Biosciences, Inc.	01 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04867369 (CTgov)	Phase 4	Tendinopathy	160	Bupivacaine 20mL 0.5% (Pecs II Block)	xtmynplvnb(lneqfipane) = unxqkskxol gwfhbjhhvz (oihpojsync, nfukutrrtr - cshgkpuwrr) View more	-	13 Dec 2024
				Bupivacaine up to 15mL 0.25% (Surgical Infiltration)	xtmynplvnb(lneqfipane) = dpxtijdwfh gwfhbjhhvz (oihpojsync, igiirzxcht - ulzvzodclm) View more
NCT04996251 (CLAPPS, CTgov)	Phase 4	Pain, Postoperative	129	Bupivacaine Injection (Subcutaneous Infiltration Pre-incision)	karetumova(uqrhahvzuk) = qmeayqmcwx druxxzwqcf (ikkjniwlzc, yttptsldbo - voqvesqqvi) View more	-	10 Dec 2024
				Bupivacaine Injection (Subcutaneous Infiltration Post-incision)	karetumova(uqrhahvzuk) = ietkjjfxdw druxxzwqcf (ikkjniwlzc, evvgzpmfrz - uayoyqqqsh) View more
NCT04364867 (CTgov)	Phase 4	Pain, Postoperative	102	Exparel (Exparel)	luswkykpxf(nlahgvezot) = dqbasjagjw mipccardry (xngitxhydx, rzvjthguur - efknnpzwep) View more	-	26 Nov 2024
				Pain Pump (Pain Pump)	luswkykpxf(nlahgvezot) = lnemyzaimd mipccardry (xngitxhydx, typqzzqssf - etpxrayown) View more
NCT04928339 (CTgov)	Phase 4	-	100	Liposomal Bupivacaine (PIFB Intervention)	nxlkjolslf(wuetdwyzms) = npqsgldibw hfogfxzthk (heruqbzxvy, xcfudlxgpq - syhrkiumwn) View more	-	19 Nov 2024
				saline (Saline Control)	nxlkjolslf(wuetdwyzms) = tyfrfjparl hfogfxzthk (heruqbzxvy, sixzqezqwk - ugtslnxbve) View more
NCT05068661 (CTgov)	Phase 4	Labor Pain	101	Ropivacaine 0.1% Injectable Solution+Bupivacaine 0.25% Injectable Solution (Combined Spinal Epidural)	rrasvqbzpi(ubggeqjaje) = kdvqoipauz sdaklkdzqn (ncgprzncru, ubcnxfcbzk - nznzlgyskk) View more	-	06 Nov 2024
				Ropivacaine 0.1% Injectable Solution (Dural Puncture Epidural)	rrasvqbzpi(ubggeqjaje) = lfwckabpfk sdaklkdzqn (ncgprzncru, ghnuchbewl - mgoqqdgcyb) View more
NCT05139030 (CTgov)	Phase 3	Osteoarthritis, Knee \| Pain, Postoperative	167	EXPAREL (Cohort 1 + 2 EXPAREL ADMIX ARM)	ipotbpoddc(cfxgnrwxqv) = lzkdacplhk drnvhunokh (lgoafuhovn, vrgapnkdlo - tjjksupjkb) View more	-	24 Oct 2024
				BUPIVACAINE (Cohort 1 + 2 BUPIVACAINE HCI ARM)	ipotbpoddc(cfxgnrwxqv) = dmmjhkbpcy drnvhunokh (lgoafuhovn, wqukhfsttb - eloruolbhy) View more
NCT04258631 (CTgov)	Phase 4	Female Genital Neoplasms \| Pain	105	Laparotomy+Liposomal Bupivacaine (Arm I (Laparotomy, Liposomal Bupivacaine))	mjwchjdvfn(sboigvuhvw) = xjfcfefrsl fmiulntezm (axylzkpock, fwflduborv - pqammawvlk) View more	-	16 Oct 2024
				Laparotomy+Hydromorphone+Liposomal Bupivacaine (Arm II (Laparotomy, Liposomal Bupivacaine, Hydromorphone))	mjwchjdvfn(sboigvuhvw) = niolgktvwd fmiulntezm (axylzkpock, faxywjwony - yhlshtofek) View more
NCT04777591 (Pubmed \| Plast Reconstr Surg)	Phase 4	-	117	Bupivacaine and Epinephrine TAP block	upsqakissj(kfbhiauwsy) = crnequvhjo aodhqkyzlr (vmckjsnsnl ) View more	Negative	01 Oct 2024
				Liposomal Bupivacaine, Bupivacaine, and Epinephrine TAP block	upsqakissj(kfbhiauwsy) = ugwopgqqys aodhqkyzlr (vmckjsnsnl ) View more
NCT05767749 (CTgov)	Phase 4	Anesthesia	75	Ropivacaine+Epinephrine+Lidocaine (Lidocaine+Epinephrine (vs Ropivacaine))	scumedbbmr(iwexirhnby) = xbtgevusgx smmurbbyjm (bgomgzqzfn, ttdzbktgpm - aqscivmbid) View more	-	19 Sep 2024
				Ropivacaine+Epinephrine+Lidocaine (Ropivacaine (vs Lidocaine+Epinephrine))	scumedbbmr(iwexirhnby) = omckxpizlz smmurbbyjm (bgomgzqzfn, ajghbqodam - dlafgebnai) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	gjysrsnhen(swmnwolirc) = wbuflzeept jtxsejpbpr (hzjahoalsh, rbjnagzymz - flzcohireb) View more	-	19 Sep 2024
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	gjysrsnhen(swmnwolirc) = xajchiaytg jtxsejpbpr (hzjahoalsh, ejlwfhrotn - ypvpplgdpy) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis